Scott Turner is currently the Chief Scientific Officer at Arda Therapeutics. Prior to joining Arda, Scott served as CSO at Pliant Therapeutics, where he played a pivotal role in the creation of Pliant's fibrosis discovery platform and spearheaded the development of their anti-fibrotic pipeline. His innovative approaches, including pioneering the use of single-cell data to dissect drug mechanisms of action and driving an advanced biomarker strategy, led to remarkable successes in achieving clinical proof of concept. Prior to Pliant, Scott lead research and development at KineMed Inc. a platform technology company developing translational biomarkers in fibrosis and metabolic disease. Scott received a PhD from University of California, Berkeley in Nutritional Sciences and Toxicology.